期刊
MODERN RHEUMATOLOGY
卷 26, 期 2, 页码 288-293出版社
SPRINGER
DOI: 10.3109/14397595.2013.859770
关键词
Biological agents; Peripheral neuropathy
类别
资金
- Mitsubishi Tanabe Pharmaceutical Company (Osaka, Japan)
- Teijin Pharma Limited (Osaka, Japan)
- AstraZeneca K.K. (Osaka, Japan)
Peripheral neuropathies should be recognized as the adverse effects of biological agents, especially anti-TNF agents. However, no solid clinical databases for biological agent-associated peripheral neuropathies (BAPN) have been established in Japan. Here we report two cases of peripheral neuropathy associated with anti-TNF agents. One was peroneal motor neuropathy. The other case was chronic inflammatory demyelinating polyradiculoneuropathy. In addition, we summarize the previous reports on BAPN and discuss their prevalence rate, pathogenesis and management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据